In patient-derived melanoma cell lines and tumor tissues, the overexpression of DSG2 was associated with poor clinical outcome primarily because DSG2 can promote vasculogenic mimicry activity in human melanoma cells [13]. The gene discussed is DSG2; the disease is neoplasm.